OmniAb (OABI) Insider Steven Love Sells 20,000 Shares
Recent insider filings show Steven Love sold 20,000 shares of OmniAb, Inc. alongside multiple other transactions on June 17, 2026.
Reviewed by automated data checks against the source filing. How we make and check alerts
Steven Love sold 20,000 shares of OmniAb, Inc. ($OABI) on June 17, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $OABI is up 12.3% after 1 week, up 4.4% after 1 month and up 126.1% to date (from the $2.03 close on Jun 17, 2026).
OABI
OmniAb, Inc.
Key Points
- Insider Steven Love sold 20,000 shares of OmniAb, Inc. on June 17, 2026.
- The biotechnology company trades near its 200-day moving average of $2.29.
- Wall Street coverage includes recent target updates from firms like Leerink Partners and StoneX.
Get $OABI trade alerts by text
We text you when insiders, Congress or big funds trade $OABI. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated OmniAb, Inc. alert may contain errors. Disclosures
Inside the Recent Trade by Steven Love
On June 17, 2026, insider Steven Love sold 20,000 shares of OmniAb, Inc. (NasdaqGM: OABI). This transaction occurred during a period of heavy internal share movement at the biotechnology firm, coming alongside several other purchases and sales reported by company insiders on the same date.
A Busy Day of Insider Transactions
The June 17, 2026 filing window captured multiple moves by company insiders. Steven Crouse, Philip Gotwals, and John Higgins each sold 20,000 shares on that day. At the same time, several of these same individuals logged acquisitions, including Steven Love picking up 40,000 shares, Steven Crouse adding 20,000 shares, and Philip Gotwals acquiring 20,000 shares.
Stock Performance and Moving Averages
Shares of OmniAb change hands around $2.34, resting close to the 200-day moving average of $2.29. The stock has experienced a wide trading band over the past year, moving between a 52-week low of $1.30 and a high of $5.43. Its 50-day moving average currently sits at $3.38.
Wall Street Ratings and Targets
Analyst coverage reflects varied perspectives on the biotechnology firm's growth path. On October 7, 2026, Leerink Partners kept an outperform rating on the stock while moving its target up to $12.00 from $10.00. On the same day, StoneX maintained its buy rating and lifted its target to $6.00 from $4.00. Earlier, on August 17, 2026, HC Wainwright & Co. reiterated a buy rating with an $11.00 price target.
What OmniAb Does
OmniAb licenses discovery research technology to pharmaceutical and biotechnology companies and academic institutions. Its platforms, such as OmniRat, OmniChicken, and OmniMouse, utilize biological intelligence to generate optimized antibody candidates for human therapeutics, supporting partners in drug development efforts.
What's Ahead for OmniAb, Inc.
Investors tracking internal transactions and market performance will watch for the company's next financial update scheduled for November 4, 2026. These reports provide ongoing insight into the firm's research partnerships and commercial progress.
Related Filing Alerts
Source: Steven Love's Form 4 filing on $OABI (Jun 17, 2026). Find the original filing: OABI Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts